ACADIA Pharmaceuticals Inc. (ACAD)

16.33
NASDAQ : Health Technology
Prev Close 15.95
Day Low/High 15.78 / 16.36
52 Wk Low/High 14.51 / 41.20
Avg Volume 3.10M
Exchange NASDAQ
Shares Outstanding 124.83M
Market Cap 1.99B
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
ACADIA Pharmaceuticals To Announce Third Quarter 2017 Financial Results On November 7, 2017

ACADIA Pharmaceuticals To Announce Third Quarter 2017 Financial Results On November 7, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Short Interest Plummets 60.7% For ACAD

Short Interest Plummets 60.7% For ACAD

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 10,064,113 share decrease in total short interest for Acadia Pharmaceuticals Inc , to 6,510,387, a decrease of 60.72% since 09/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

The Plymouth Meeting, Pa.-based firm said a Phase 1 study of Zika vaccine GLS-5700 'induced high levels of binding antibodies in 100% of participants.'

ACADIA Pharmaceuticals Initiates Phase III Study Of Pimavanserin In Dementia-Related Psychosis

ACADIA Pharmaceuticals Initiates Phase III Study Of Pimavanserin In Dementia-Related Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the initiation of HARMONY, a Phase III study to evaluate pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis,...

ACADIA Pharmaceuticals To Present At The Ladenburg Thalmann 2017 Healthcare Conference On September 26, 2017

ACADIA Pharmaceuticals To Present At The Ladenburg Thalmann 2017 Healthcare Conference On September 26, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Biotech M&A: Who's Next After Gilead-Kite?

Biotech M&A: Who's Next After Gilead-Kite?

Prospects for acquisition activity in the sector are improving.

'Longing' for Acadia Pharmaceuticals? Here's How to Play It

'Longing' for Acadia Pharmaceuticals? Here's How to Play It

ACAD looks strong enough for a rally at least to the upper $30s.

3 Housing Plays With Solid Earnings

3 Housing Plays With Solid Earnings

These names are building a sound foundation for growth.

ACADIA Pharmaceuticals Reports Second Quarter 2017 Financial Results

ACADIA Pharmaceuticals Reports Second Quarter 2017 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

ACADIA Pharmaceuticals To Announce Second Quarter 2017 Financial Results On August 8, 2017

ACADIA Pharmaceuticals To Announce Second Quarter 2017 Financial Results On August 8, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Named To Forbes Magazine's List Of World's Most Innovative Growth Companies

ACADIA Pharmaceuticals Named To Forbes Magazine's List Of World's Most Innovative Growth Companies

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it has been ranked 11 th on Forbes Magazine's 2017 list of the World's Most Innovative Growth Companies.

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

Here are the activist investor's next potential targets.

Jana Partners Liquidates Whole Foods Stake After Engineering Industry-Transforming Sale To Amazon

Jana Partners Liquidates Whole Foods Stake After Engineering Industry-Transforming Sale To Amazon

The activist will gain $320 million on the sale, which suggests that the fund either doesn't believe a higher bidder is coming or that they need the cash.

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

My three top predictions for the next six months.

3 Fearless Predictions for the Second Half

3 Fearless Predictions for the Second Half

The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.

3 Fearless Predictions for the Second Half

3 Fearless Predictions for the Second Half

The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.

The Activist Who Pushed Whole Foods Into the Arms of Amazon Could Target These Companies Next

The Activist Who Pushed Whole Foods Into the Arms of Amazon Could Target These Companies Next

Here are the activist investor's next potential targets.

Non-FANG Stocks May Finally Get Some Love

Non-FANG Stocks May Finally Get Some Love

Tech meltdown provides an opportunity for rotation into undervalued sectors.

4 Undervalued Biotech Stocks

4 Undervalued Biotech Stocks

Two are turnaround stories, and two are oversold.

Keep Biotech Trigger Fingers Holstered

Keep Biotech Trigger Fingers Holstered

Three names show how fast biotechs can become oversold when the market acts in knee-jerk fashion.

3 Post-Earnings Biotech Buys

3 Post-Earnings Biotech Buys

These names are now undervalued, despite solid results and good fundamentals.

3 Post-Earnings Biotech Buys

3 Post-Earnings Biotech Buys

These names are now undervalued, despite solid results and good fundamentals.

ACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Healthcare Conference On May 16, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals To Announce First Quarter 2017 Financial Results On May 9, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Takeaways and Observations; What's Driving My Approach: Doug Kass' Views

Takeaways and Observations; What's Driving My Approach: Doug Kass' Views

Doug Kass shares his thoughts on Twitter, Apple and Alphabet.

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.

2 Biotech Pullback Targets

2 Biotech Pullback Targets

Acadia and Neurocrine both have catalysts for growth; buy any weakness.

I'm Big on Housing Entering Quarter No. 2

I'm Big on Housing Entering Quarter No. 2

Home builders make up the second-largest allocation in my portfolio, behind biotech.

What Poker Taught Me About Investing

What Poker Taught Me About Investing

I've learned that emotions have little use at a poker table; they don't in the stock market, either.

TheStreet Quant Rating: D- (Sell)